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Abstract
Due to the risk of severe vaccine-associated adverse events, yellow fever vaccination in Brazil is only recommended in areas
considered at risk for disease. From September 2008 through June 2009, two outbreaks of yellow fever in previously
unvaccinated populations resulted in 21 confirmed cases with 9 deaths (case-fatality, 43%) in the southern state of Rio
Grande do Sul and 28 cases with 11 deaths (39%) in Sao Paulo state. Epizootic deaths of non-human primates were reported
before and during the outbreak. Over 5.5 million doses of yellow fever vaccine were administered in the two most affected
states. Vaccine-associated adverse events were associated with six deaths due to acute viscerotropic disease (0.8 deaths per
million doses administered) and 45 cases of acute neurotropic disease (5.6 per million doses administered). Yellow fever
vaccine recommendations were revised to include areas in Brazil previously not considered at risk for yellow fever.
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Introduction
Yellow fever is an acute viral hemorrhagic disease transmitted
by mosquitoes. Severity ranges from self-limited febrile illness to
hemorrhagic syndrome with jaundice, multiple organ failure and
death; severe cases are more likely to be detected and reported to
passive surveillance systems [1,2]. Yellow fever is considered
endemic in tropical regions of Africa and South America. For
endemic countries, the World Health Organization recommends
vaccination of persons living in areas at-risk for yellow fever, as
well as for epidemic control [3]. According to the 2010 revised
yellow fever risk map, Brazil is one of 11 South American
countries with endemic or transitional areas for yellow fever, and
one of seven in which vaccine is recommended in only part of the
territory [4].
In Brazil, yellow fever virus transmission is maintained in
tropical forests in a sylvatic cycle first described in the 1930s [5],
involving non-human primates and several species of tree-dwelling
mosquitoes. Since several New World monkeys species develop
fatal disease following yellow fever viral infection [2], sudden die-
offs of non-human primates may signal yellow fever virus
circulation and a potential exposure risk to humans. Surveillance
for epizootic disease is recommended by the Pan American Health
Organization [6], and is conducted in several Brazilian states as an
early warning system for viral circulation to inform preventive
vaccination [7]. In Brazil, sporadic human cases may also occur as
a result of recreational or occupational exposures to jungle areas
[8,9].
Yellow fever vaccine developed from attenuated viral strains has
been used in Brazil since 1939 [10]. Yellow fever vaccine
recommendations must weigh the risk of exposure to yellow fever
virus against the rare occurrence of fatal adverse events among
vaccinated individuals [11,12]. The Brazilian Ministry of Health
recommends vaccination against yellow fever for persons who
reside in or visit areas where transmission of yellow fever virus
occurs [13]. However, yellow fever virus may also be transmitted
from human to human by Aedes mosquitoes, resulting in urban
epidemics. Although Brazil successfully controlled urban trans-
mission in the 1940s through vector control and vaccination [14],
re-establishment of Aedes aegypti in urban areas has resulted in
recurrent epidemics of dengue fever and poses a risk for outbreaks
of urban yellow fever [15–17]. Brazil’s national yellow fever
control strategy seeks to prevent human disease by identifying
areas where the virus circulates, as well preventing re-introduction
of urban epidemics through mass vaccination [11].
Since 1999, yellow fever has re-emerged in parts of Brazil that
had been silent for several decades [9,18–21], challenging
prevention strategies and resulting in frequent revision of yellow
fever vaccine recommendations [13]. Beginning in 2008, following
yellow fever outbreaks in central and southeastern Brazil,
northeastern Argentina and Paraguay [4], the Ministry of Health
initiated enhanced surveillance for human and epizootic yellow
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fever viral activity during the usual seasonal period from October
to June [8]. We describe two yellow fever outbreaks that occurred
during the first year of enhanced yellow fever surveillance in
Brazil, during the 2008–2009 season.
Methods
Ethics statement
This study involved analysis of routinely collected surveillance
data and did not require ethical review according to the Brazilian
National Committee for Ethics in Research. Personally identifiable
information (patient name and information included on case
report form) was available only to surveillance officers and was not
used in this study.
Surveillance methods and definitions
Yellow fever is a notifiable disease in Brazil. The national
passive surveillance system of the Brazilian Ministry of Health
receives reports of suspected cases of yellow fever and epizootic
events from state and municipal health departments. Beginning in
2008, the Ministry of Health took several actions to increase
sensitivity of surveillance and timeliness of response vaccination
during the seasonal period of highest risk of yellow fever from
October to June. Enhanced surveillance includes raising awareness
of yellow fever among health workers, mandatory notification of
persons with ictero-hemorrhagic syndromes, investigation of
human deaths due to unknown causes, intensification of epizootic
surveillance in non-human primates and immediate communica-
tion of investigation findings. The national yellow fever surveil-
lance system coordinates epidemiological surveillance for human
cases and epizootic events, as well as communication between
health departments and public health laboratories and [13].
Suspected cases are defined as individuals presenting with fever
accompanied by jaundice or hemorrhagic symptoms, who within
the previous 15 days were exposed to areas considered at-risk of
yellow fever or with evidence of yellow fever virus circulation.
Suspected cases in persons who received their first yellow fever
vaccination within 10 days prior to symptom onset are classified
for surveillance as unvaccinated. Persons presenting with signs and
symptoms of yellow fever (jaundice, abnormal laboratory values,
hemorrhage or neurologic symptoms) who experienced symptom
onset within 60 days of receipt of yellow fever vaccine identified
through enhanced surveillance for ictero-hemorrhagic syndromes
were investigated following a clinical and laboratory protocol as
possible adverse reactions to vaccination [22]. Adverse events were
classified as confirmed, probable, suspected, discarded or incon-
clusive, according to U.S. Centers for Disease Control and
Prevention criteria [23]. Clinical, epidemiological and laboratory
data, as well as vaccination history, are reviewed by expert
committee that provides recommendation for final classification as
previously described [22].
Laboratory confirmation for human cases includes the presence
of yellow fever virus-specific antibodies detected by IgM-capture
ELISA [24] or immunohistochemistry [25,26], detection of
yellow fever virus by reverse-transcriptase PCR [27] or isolation
of yellow fever virus in cell culture [28]. Nucleotide sequencing of
yellow fever virus is used to differentiate between wild-type viral
infections and vaccine virus [27,29].
An epizootic is defined as a sudden die-off of non-human
primates in a small geographic area. Sightings of sick and dying
monkeys or carcasses are reported to local health departments,
which conduct investigations and collect specimens for laboratory
testing. Epizootics of yellow fever are confirmed if: 1) yellow fever
virus is detected by immunohistochemistry or reverse-transcriptase
PCR or isolated from animal specimens [7,20,30], or 2) if multiple
non-human primate deaths are clustered within a short time
period or linked by similar hydrographic features or vegetation to
neighboring areas with documented circulation of yellow fever
virus.
A yellow fever outbreak is defined as two or more confirmed
human cases with a common probable location of infection. In
accordance with International Health Regulations, evidence of
yellow fever virus circulation in an area in which the resident
population has not been vaccinated against yellow fever is
classified by the Brazilian Ministry of Health as a Public Health
Emergency of National Importance, requiring immediate evalu-
ation of the risk of viral dissemination and need for intervention
[31,32]. Recommendations for vaccination against yellow fever
virus may be extended to ‘‘affected areas’’ (municipalities with
confirmed yellow fever human cases or epizootics, or detection of
yellow fever virus in mosquito vectors) and bordering municipal-
ities. During yellow fever outbreaks, vaccination may be recom-
mended beginning at 6 months of age; yellow fever is not
recommended in infants younger than 6 months of age [3,23].
Statistical analysis
Surveillance data were tabulated in TabWin (version 3.2,
Datasus, Brazilian Ministry of Health, Rio de Janeiro, Brazil) and
maps were created in TerraView (version 3.2.1, INPE, São José
dos Campos, Brazil). Analyses were conducted in EpiInfo (version
6.04d, Centers for Disease Control and Prevention, Atlanta, USA).
Incidence of yellow fever was calculated as the number of
confirmed cases divided by the total state population, stratified
according to areas with or without yellow fever vaccination
recommendations prior to the 2008–2009 outbreaks. Rates of
adverse events were calculated per million doses administered in
each state during the period.
Results
Yellow fever surveillance in humans
During the epidemic period from 28 September 2008 through 6
June 2009, 270 suspected yellow fever cases were reported to the
Brazilian Ministry of Health. Of the suspected cases, 50 cases were
classified as confirmed yellow fever based on laboratory criteria
Author Summary
Yellow fever is a viral hemorrhagic disease transmitted by
mosquitos, endemic in tropical regions of Africa and South
America. Large urban outbreaks of yellow fever have been
eliminated in the Americas, where most yellow fever cases
result from human exposure to jungle or forested
environments. Vaccination is effective but carries a risk of
potentially fatal adverse events in a small number of
vaccinees. In a large country such as Brazil, vaccination is
recommended only in areas where there is a risk of
exposure to yellow fever virus. We describe two outbreaks
of yellow fever in areas without yellow fever vaccine
recommendations. Numerous epizootics, or die-offs of
non-human primates, were reported from areas with
human cases. In response to the outbreaks and epizootic
activity, over five million doses of vaccine were adminis-
tered in previously unvaccinated populations, resulting in
vaccine associated adverse events, six of which were fatal.
The outbreaks resulted in expansion of areas with yellow
fever vaccine recommendations, and highlight the need
for safer yellow fever vaccines.
Yellow Fever Outbreaks in Brazil
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(n = 46) or epidemiologic linkage (n = 4). In the southernmost state
of Rio Grande do Sul, there were a total of 21 confirmed cases (2.1
cases per million residents) with 9 deaths (case-fatality, 43%),
including 3 cases (5.0 per million residents) in areas in which
yellow fever vaccine was recommended and 18 cases (1.9 per
million residents) in areas without vaccine recommendation prior
to the outbreak (Figure 1a). In the most populous state of São
Paulo, there were 28 confirmed cases (2.7 per million residents)
with 11 deaths (case-fatality, 39%), all in areas without vaccine
recommendations prior to the outbreak (Figure 1c). During the
same period, only 1 (non-fatal) confirmed case (0.3 cases per
million residents) resulting from sporadic exposure was reported
from Mato Grosso state in central Brazil. Among other suspected
cases, 196 (89.1%) were negative for antibodies to yellow fever and
were classified as non-yellow fever cases and another 24 (10.9%)
suspected cases had no epidemiological link with areas of
transmission of yellow fever or had evidence of disease due to
other causes that included dengue, leptospirosis, hantavirus
infection and sepsis.
Among confirmed case patients, 35 (70%) were male; median
age was 31 years (range, 3 days to 73 years). Characteristic
symptoms of jaundice and hemorrhage were recorded on case
report forms for only 17 (34%) and 18 (36%) confirmed cases,
respectively, although transaminase levels were markedly elevated
(Table 1). 37 (74%) were hospitalized for more than 24 hours and
overall case-fatality was 40%. Age and gender distribution was
similar among confirmed cases in the two most affected states.
One case patient with laboratory-confirmed yellow fever had
received yellow fever vaccine 9 years earlier; none of the other case
patients was considered effectively vaccinated. However, three
individuals had received vaccine 1 to 2 days prior to experiencing
symptom onset and were investigated as possible vaccine-
associated adverse events; wild-type yellow fever infection was
confirmed in two case patients by nucleotide sequencing while
wild-type infection was considered most likely in the third case
patient based on epidemiologic linkage to a laboratory-confirmed
case. Four additional case patients received yellow fever vaccine
after the onset of symptoms; identification of yellow fever virus
confirmed wild-type infection in three case patients while the
fourth case patient was classified as confirmed based on exposure
to areas with yellow fever virus circulation prior to symptom onset.
A total of 46 (92%) confirmed cases occurred in areas in which
vaccination against yellow fever had not been recommended prior
to the 2008/2009 season (Figure 2). Probable locations of exposure
for all confirmed cases were forested or rural areas, except for one
case of perinatal exposure in an 8-day old infant [33]. The
majority of cases were clustered in a small number of municipal-
ities, including five in São Paulo state (Piraju [n = 11], Sarutaiá
[n = 7], Buri [n = 5], Avaré [n = 4] and Tejupa [n = 1]) and nine in
Rio Grande do Sul (Santa Cruz do Sul [n = 7], Vera Cruz [n = 4],
St. Angelo [n = 3], Pirapó [n = 2], Bossoroca [n = 1], Espumoso
[n = 1], Jóia [n = 1], Ijuı́ [n = 1], and Augusto Pestana [n = 1]). Of
14 municipalities in the two states identified as probable location
of exposure of confirmed human cases, 12 were not previously
Figure 1. Notifications of suspected cases of human yellow fever and epizootics among non-human primates. Rio Grande do Sul state
(Figures 1a and 1b) and São Paulo state (Figures 1c and 1d). Data from the national yellow fever surveillance system according to week of occurrence,
October 2008–June 2009, and final classification of cases and epizootics: confirmed, discarded (laboratory negative) and unconfirmed (classified as
death of non-human primate when no specimens were available for testing).
doi:10.1371/journal.pntd.0002740.g001
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considered at-risk for yellow fever and vaccination of residents had
not been recommended prior to the epidemic. Yellow fever
vaccination was recommended prior to the outbreak in two
municipalities in northwestern Rio Grande do Sul following
detection of yellow fever virus circulation in 2002 [30].
Yellow fever surveillance in non-human primates
Epizootic activity involving deaths of non-human primates
preceded human cases in both states that experienced yellow fever
outbreaks (Figure 1). In Rio Grande do Sul, epizootic surveillance
registered 950 reports of deaths among non-human primates
during the period of enhanced surveillance; 947 [99%] involving
howler monkeys of the genus Alouatta. Yellow fever virus
circulation was confirmed in 173 (67%) of 259 events with
samples available for testing, and 7 were confirmed by epidemi-
ological linkage (Figure 1b). In Sao Paulo, 125 epizootics were
reported and totaled 146 dead animals. Of these, 67 were of the
genus Alouatta (45.9%), 56 Callithrix (38.3%), 14 Cebus (9.6%) and 9
were not identified (6.2%). Biological specimens were collected for
testing from 64 (44%) of 146 animal carcasses, including tissue
specimens from 58 animals and blood specimens from 23; the
presence of yellow fever virus was detected in specimens from 2
separate epizootics (Figure 1d). Although 238 epizootic events
were reported from other states, only 1 from Paraná state was
confirmed as yellow fever.
In Rio Grande do Sul, epizootics were reported from all but one
municipality identified as probable locations of exposure of
confirmed human cases, and circulation of yellow fever virus
among non-human primates was detected in the state 9 weeks
before the occurrence of human cases (Figures 1a and 1b). In São
Paulo, despite reports of epizootic activity throughout the
epidemic period, yellow fever virus circulation among non-human
primates was not confirmed until late March, 2009, following
occurrence of human cases in late February 2009 (Figures 1c and
1d). In all, circulation of yellow fever virus was documented in 78
municipalities: 71 (91%) with confirmed epizootic activity (includ-
ing 7 with both human and animal disease) and only 7 (9%) with
confirmed human cases without confirmed epizootics.
Vaccination
Prior to the outbreak in Rio Grande do Sul, yellow fever
vaccination had been recommended in 59 municipalities in the
northwest corner of the state (595,346 inhabitants); during and
following the outbreak, vaccination was extended to 462
municipalities (93% of all municipalities in the state, with
9,963,267 residents), leaving only a small region along the Atlantic
coast without vaccine recommendation. Following extension of
yellow fever vaccine recommendations to affected areas, 3,636,722
doses of yellow fever vaccine were administered in Rio Grande do
Sul (Figure 1a), reaching approximately 39% vaccination coverage
in previously unvaccinated populations.
In São Paulo state, the number of municipalities with yellow
fever vaccine recommendations increased from 332 (with
7,584,215 residents) to 452 (with 10,469,327 residents), covering
70% of the state and approaching metropolitan São Paulo. A total
of 1,869,960 vaccine doses were administered in previously
unvaccinated areas (Figure 1c), reaching 64% of the resident
population.
In all, 5,506,682 million doses (69% of all doses administered in
Brazil during the period) were administered in areas in which
vaccination against yellow fever had not been recommended before
the epidemic. In both states, numbers of doses administered peaked
after the confirmation of human cases (Figure 1), although municipal-
ities were included in the area with yellow fever vaccine recommen-
dation at different times as the epidemic spread to new areas.
Severe adverse events following yellow fever vaccination
During the same period, Brazil’s national immunization
program received 97 reports of severe adverse events among
individuals who received yellow fever vaccine. Of these, 51 were
classified by the national vaccine safety committee as associated
with yellow-fever vaccine, including 6 cases of acute viscerotropic
disease (incidence, 0.8 cases per million doses administered in
Brazil), all of which were fatal, and 45 cases of acute neurologic
disease (5.6 per million doses administered in Brazil) with no
deaths. Of these, 40 cases (89%) were classified as aseptic
meningitis; three cases (7%) were reported as encephalitis, one
case was diagnosed as meningoencephalitis and one case as a right
peripheral facial paralysis. However, two of the patients who had
meningoencephalitis and encephalitis developed neurological
sequelae that included difficulty walking and decreased visual
acuity, respectively. Among the 6 confirmed cases of yellow fever
vaccine-associated acute viscerotropic disease, median age was 31
years (range 4–44 years) and 2 (33%) case patients were male.
Table 1. Patient characteristics, clinical findings and
laboratory values for laboratory-confirmed yellow fever, Brazil,
2008–2009.
Variables N = 50 (%)
Male gender 35 (70)
Age in years, median 31




Abdominal pain 20 (40)





Aspartate transaminase, mean mg/dl (range) 5132.2 (32–28900)
Alanine transaminase, mean mg/dl (range) 2480 (19–12600)
Total bilirubin, mean mg/dl (range) 4.6 (0–26)
Direct bilirubin, mean mg/dl (range) 2.7 (0.1–19.1)
Creatinine, mean mg/dl (range) 78 (13–280)
Urea, mean mg/dl (range) 4.2 (0.6–15)
Yellow fever confirmation
IgM capture ELISA or immunohistochemistry 40 (80)
Viral isolation 1 (2)
Nucleic acid dectection 16 (32)
Histopathology 1 (2)
Epidemiologic linkage 4 (8)
Evolution
Hospitalized .24 hours 37 (74)
Died 20 (40)
*1 confirmed case reported yellow fever vaccination nine years earlier; excludes
3 case patients with yellow fever vaccination 1–2 days before onset of
symptoms.
doi:10.1371/journal.pntd.0002740.t001
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Rates of vaccine-associated viscerotropic disease in the three states
that reported cases ranged from 0.4 to 1.6 cases per million doses
administered (Table 2). Among the 45 confirmed cases of yellow
fever vaccine-associated acute neurologic disease, median age was
21 years (range 22 days - 66 years) with 26 (58%) cases among
males. Rates of neurologic disease in the three states ranged from
0.8 per million doses administered in Santa Catarina to 11.0 per
million in Rio Grande do Sul (Table 2). Two events were classified
as vaccine-associated neurologic disease resulting from secondary
transmission to breastfed infants [34,35].
Discussion
These two yellow fever outbreaks in unvaccinated populations
in the Brazilian states of Rio Grande do Sul and São Paulo during
the 2008–2009 epidemic season challenged control strategies and
Figure 2. Location of confirmed epizootic events and human cases of yellow fever, Brazil, 2008–2009 (insets: states of São Paulo
and Rio Grande do Sul).
doi:10.1371/journal.pntd.0002740.g002
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resulted in revised vaccination guidelines for Brazil. Despite the
relatively small number of confirmed cases and deaths, both
outbreaks occurred in geographic areas without yellow fever
vaccination recommendations, in which circulation of yellow fever
virus had not been identified for four decades [9]. Although
control vaccination was rapidly implemented following identifica-
tion of human cases and epizootic events, the virus spread more
quickly than expected and human cases continued to occur in
newly affected areas. The experience in Rio Grande do Sul
demonstrates the importance of active surveillance for yellow fever
epizootics among non-human primates to inform vaccine recom-
mendations [7]. Mass vaccination in previously unvaccinated
populations may have prevented additional cases, but most
vaccination occurred after the peak of the outbreaks. Yellow fever
vaccine was associated with six deaths and multiple severe vaccine-
related adverse events. Additional strategies are needed to prevent
yellow fever outbreaks in unvaccinated populations until safer
vaccines are available.
Mass vaccination has been associated with increased detection
of adverse events since the first description of yellow fever vaccine-
associated viscerotropic disease during intensified yellow fever
vaccination in Brazil [22,36,37]. Vaccination of adults without
prior immunity may increase rates of severe events, since risk is
greatest with first vaccination and appears to increase with age
[38,39]. In addition, although detection rates of viscerotropic
disease in Brazil are lower than estimated incidence based on
United States surveillance data (0.4 per 100,000 doses adminis-
tered) [39], improved surveillance during mass vaccination likely
contributes to increased detection of adverse events [22]. The
2008–2009 outbreaks were the first in Brazil to identify rates of
vaccine-associated neurotropic disease similar to those reported
from adverse events surveillance in the United States (0.8 per
100,000 doses administered) [39], suggesting that enhanced
surveillance and laboratory testing (specifically, real-time PCR
for detection of yellow fever virus RNA in cerebrospinal fluid
specimens) improved detection of neurologic events. Brazilian
authorities have proposed universal childhood immunization
against yellow fever to decrease risk of severe vaccine-associated
adverse events later in life [11], based on the lower risk of
viscerotropic disease in young children. However, due to
uncertainty about the true risk, yellow fever vaccine is included
in routine childhood immunizations only in Brazilian municipal-
ities where vaccine is recommended for the entire population [40].
Factors associated with emergence of yellow fever are still
poorly understood. It is unclear why yellow fever re-emerged in
two non-endemic areas more than 1000 kilometers apart with
limited evidence of viral circulation in other parts of Brazil. There
had been widespread evidence of virus circulation in central
Brazil during the preceding epidemic season (October 2007—
June 2008), with confirmed human cases in 8 states and reports of
epizootics in 14 states [8]. Circulation of yellow fever virus had
been confirmed in northern São Paulo state and the western part
of Paraná state (between Rio Grande do Sul and São Paulo) in
early 2008. The role of climatic events (increased temperatures
and high rainfall), high densities of susceptible non-human
primate hosts and human exposure to mosquito vectors in
forested areas may all have contributed [9]. Conditions may have
favored viral spread to populations of susceptible non-human
primate hosts during the interepidemic period, seeding outbreaks
in the two previously unaffected areas. Better understanding of
factors affecting viral spread and the dynamics of viral
transmission would help to focus preventive immunization in
unvaccinated populations.
As a result of the 2008–2009 outbreaks, Brazil’s yellow fever risk
map was revised in 2010 to include large areas in which the
population had not previously been vaccinated (Figure 3). This
followed a change in 2008 by the Brazilian Ministry of Health to
simplify classification of municipalities as those in which yellow
fever vaccination is recommended or those without recommen-
dation [13]. The 2008 revision harmonized state and federal
recommendations, and the 2010 revision added vaccine recom-
mendations in 334 municipalities in four states, with an estimated
population of 8.6 million residents. In 2013, WHO revised yellow
fever vaccine recommendations based on evidence that a single
dose of YF vaccine confers life-long immunity against YF disease
in most vaccine recipients, suggesting that booster doses may not
be necessary [3]. However, cases of yellow fever have infrequently
been documented in vaccinated individuals [3], as observed in one
individual during the 2008–2009 outbreaks [13]. The Brazilian
Ministry of Health continues to recommend re-vaccination against
yellow fever every 10 years in areas considered at-risk for yellow
fever, although priority is given to primary vaccination of
previously unvaccinated persons in these areas. Vaccine recom-
mendations may be revised as data become available from
ongoing studies on the duration of immunity provided by yellow
fever vaccine in adults and children.






Median interval from vaccination to
symptom onset, days (range)
State
Viscerotropic disease 6 (6) 2 (33) 31 (4–44) 0.8 3.5 (2–5)
Rio Grande do Sul 2 (2) 1 (50) 39 (39) 0.5 4.5 (4–5)
São Paulo 3 (3) 1 (33) 30 (4–44) 1.6 3.0 (2–3)
Santa Catarina 1 (1) 0 23 0.4 4.0
Neurologic disease 45 (0) 26 (58) 21 (0**–66) 5.6 17 (2–40)
Rio Grande do Sul 40 (0) 23 (58) 22 (0**–66) 11.0 19 (2–40)
São Paulo 3 (0) 2 (67) 24 (19–32) 1.6 9 (7–15)
Santa Catarina 2 (0) 1 (50) 4 (2–6) 0.8 17 (13–21)
* Cases per million yellow fever vaccine doses administered during outbreak response.
**Includes 22-day old infant with vaccine-associated neurologic disease following secondary transmission of yellow fever vaccine virus through breastfeeding [35].
doi:10.1371/journal.pntd.0002740.t002
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During the past decade, from 2000 to 2010, the majority of
human cases have been associated with exposures outside the
Amazon River basin as yellow fever re-emerged in previously
silent areas and unvaccinated individuals entered natural
environments where yellow fever viruses circulate. As a result
of changes in the epidemiology of yellow fever, the Brazilian
Ministry of Health adopted new surveillance strategies, including
enhanced monitoring of yellow fever virus activity during the
epidemic season [13]. During the 2008–2009 epidemic season,
enhanced surveillance contributed to improved laboratory
diagnosis of suspected cases, detection of epizootic activity in
affected areas and identification of vaccine-associated adverse
events, especially neurologic disease. Earlier detection and
treatment or more sensitive surveillance may be associated with
lower case-fatality observed during 2008–2009 (40%) compared
to the 2007–2008 season, with 49 confirmed cases and 28 (57%)
deaths (Brazilian Ministry of Health, unpublished data). However,
epizootic surveillance can only be effective in preventing human
cases if there is adequate time to vaccinate or alert the population at-
risk to avoid exposure of susceptible individuals. While active
surveillance informed preventive vaccination in Rio Grande do Sul,
epizootic events near São Paulo were not reported until after the
outbreak had occurred. Additional strategies prioritized by the
Ministry of Health included monitoring vaccination coverage in
areas with yellow fever vaccine recommendations, syndromic
surveillance for febrile icterohemorrhagic diseases for early case
detection and surveillance for adverse events following yellow fever
vaccination.
Figure 3. Evolution of geographic risk classification for yellow fever vaccination recommendations in Brazil, 2001–2010.
doi:10.1371/journal.pntd.0002740.g003
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To prevent outbreaks as well as sporadic cases, public health
authorities need to intensify efforts to ensure that individuals at
highest risk of exposure are vaccinated. Unvaccinated individuals
traveling to areas where vaccination is recommended should be
vaccinated at least 10 days prior to travel. Public education is
needed about the risk of disease and indications for vaccination,
including contraindications and precautions for persons who
might be at increased risk of severe adverse events. Efforts should
also continue to develop a safer vaccine [41].
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